However, CMS announced the Medicare GLP-1 Bridge demonstration in December 2025, which will allow Medicare beneficiaries to access GLP-1 obesity medications starting July 2026 , with a longer-term BALANCE Model launching in Medicare Part D by January 2027 ( [18] )
Researchers reported the number of colorectal cancer diagnoses after a 6-year period for Group 1 (those who took GLP-1s) and a 5-year period for Group 2 (those who took aspirin)
Cheng A, Hu L, Wang Y, Huang L, Zhao L, Zhang C, et al
Compounding pharmacy options Multiple compounding pharmacies provide semaglutide, and they differ in formulation, quality control, and pricing
Dexamethasone (DEX) inhibits inflammation and cartilage damage by influencing both synoviocytes and chondrocytes